GLP-1 drugs and Mounjaro: what makes tirzepatide different?

What does it mean to call Mounjaro a GLP-1 drug?

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after eating. It slows the rate at which the stomach empties, reduces appetite signals in the brain, and nudges the pancreas to produce insulin when blood sugar rises. Most weight-loss medicines in this class work by mimicking that one hormone, and you can read more about how GLP-1 relates to Mounjaro if you want a deeper explanation of that relationship. Mounjaro does that, and also mimics GIP (glucose-dependent insulinotropic polypeptide) a second gut hormone that works on appetite and fat storage through a slightly different set of pathways.

The combination matters in practice. Activating both receptors appears to produce a stronger appetite-suppressing and metabolic effect than either pathway alone, which is reflected in the trial data. Tirzepatide's full mechanism is still being studied in post-market research, which is why it carries the Black Triangle designation, but the dual-agonist principle is well-established and is documented in detail in the NHS tirzepatide medicines page.

The distinction also matters when patients ask whether Wegovy and Mounjaro are the same thing. They are both described as GLP-1 medicines (that is technically accurate) but if you want to understand exactly what kind of GLP medicine Mounjaro is, that page sets out how tirzepatide differs from single-agonist options. Tirzepatide is the only dual-agonist in UK clinical use for weight management, and they are made by different manufacturers, carry different licensed dose schedules, and have separate trial programmes behind them. You can read more about how tirzepatide sits within the broader tirzepatide drug class if you want the fuller picture.

What does the trial evidence actually show for this class of GLP-1 drug?

A question our prescribers hear most weeks is some version of: "How much weight will I actually lose?" The honest answer is that trials report averages, and individual results vary based on starting weight, dose reached, and lifestyle changes made alongside treatment.

That said, the numbers from SURMOUNT-1 are striking. Across 2,539 adults with obesity and no diabetes, those on the 15 mg dose lost an average of around 20–21% of their body weight over 72 weeks, figures that led NICE to recommend tirzepatide for NHS use in its technology appraisal TA1026, published in December 2024. In the 2025 SURMOUNT-5 head-to-head trial, tirzepatide also produced greater average weight loss than semaglutide 2.4 mg over the same period. Trial averages do not translate to personal guarantees, and results depend on reaching and tolerating the higher doses, but tirzepatide has the strongest weight-loss evidence of any UK-licensed injection in this class.

For context on how the evidence compares across different weight-loss drugs, and to see where Mounjaro sits among other drugs in its category, the distinction between single and dual receptor action is central to understanding the gap in outcomes.

Who can access Mounjaro as a GLP-1 medicine, and through which routes?

The licensed eligibility for tirzepatide covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnoea, or cardiovascular disease. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone never guarantees a prescription, a prescriber looks at the full picture, including current medicines, relevant history, and any contraindications.

On the NHS, access follows a phased rollout tied to NICE TA1026: from June 2025, those with a BMI of 40 or above and four or more of five qualifying conditions could access tirzepatide through NHS pathways; a second cohort covering BMI 35–39.9 opened in June 2026. GP practices may prescribe under the 2026/27 QOF contract, though participation varies by practice. Waiting times can be significant, and not everyone will meet the NHS thresholds.

Private prescription is the alternative for those who do not meet NHS criteria, or who prefer not to wait. If you want to understand what treatment costs typically look like, the Mounjaro cost page gives factual context on UK private pricing. For a broader view of how tirzepatide fits within weight-loss treatment options more generally, that page covers the landscape clearly.

What side effects should people know about before starting a GLP-1 like Mounjaro?

The side-effect profile for tirzepatide is dominated by gastrointestinal symptoms: nausea, constipation, diarrhoea, indigestion, bloating, and occasionally vomiting. These are most noticeable in the early weeks and after each dose increase, and they typically ease as the body adjusts. Injection-site reactions, headache, fatigue, and dizziness are also reported.

A smaller number of people experience more serious effects. Acute pancreatitis is uncommon but can be serious: severe stomach pain that radiates to the back, with or without vomiting, needs urgent medical attention. The MHRA issued specific guidance on this risk for GLP-1 medicines in early 2026. Gallbladder problems are also a recognised risk with rapid weight loss in this class. Patients who develop significant dehydration from persistent vomiting or diarrhoea should seek medical advice promptly.

Mounjaro is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for use in those under 18. Women taking the oral contraceptive pill should use an additional non-oral method for the first four weeks of treatment and after each dose increase, because tirzepatide's effect on gastric emptying can reduce pill absorption, this is specific to tirzepatide and does not apply to semaglutide in the same way.

A full side-effect and safety profile is set out in the Patient Information Leaflet supplied with each pen, and in the NHS tirzepatide information page. Our FAQs also cover some of the practical questions patients raise most often. If something doesn't feel right on treatment, the aftercare team at contact is available seven days a week, and for anything urgent, seek medical help directly.

If you'd like to discuss whether tirzepatide is appropriate for your situation, start your free consultation with our clinical team. A GPhC-registered prescriber reviews every application the same day.